NOV 11, 2015 6:00 AM PST

Clinical next-generation sequencing for precision cancer therapeutics

Speakers
  • Associate Director, Genetics and Solid Tumor Diagnostics Laboratory, Assistant Professor, Department of Laboratory Medicine, University of Washington
    Biography
      Dr. Lockwood joined the Department of Laboratory Medicine as an Associate Director of the Genetics and Solid Tumor Diagnostics Laboratory at the University of Washington Medical Center in 2014. She is a Diplomate of the American Board of Clinical Chemistry and an Active Candidate of the American Board of Medical Genetics and Genomics. After obtaining her PhD at the University of Wisconsin, Dr. Lockwood completed postdoctoral fellowship training in Clinical Chemistry and Clinical Molecular Genetics at the Washington University School of Medicine in St. Louis, MO. Her interests include the development and application of molecular methods for the detection of genomic alterations in genetic disease, hematologic malignancies, and solid tumors. Dr. Lockwood has also been active in the design and implementation of educational resources related to training in genomic medicine.

    Abstract:

    Next-generation sequencing has emerged as a valuable tool for generating patient-specific genetic information for clinical diagnostics and optimal selection of targeted therapies. The heterogeneous somatic mutational landscape in cancer makes NGS technologies particularly appealing due to their ability to accurately and simultaneously detect multiple mutations across many genes.  Accordingly, oncologists are increasingly recognizing the importance of mutation assessment prior to initiating therapy with targeted therapeutic agents.  Issues that must be considered with NGS include technological limitations and opportunities, bioinformatics, test validation requirements, and reporting complexities. Participants will better understand and assess current clinical NGS testing modalities, including the necessary steps required for selecting a NGS assay.  The presentation will specifically emphasize the utility of NGS testing in precision oncology with illustrative case examples.

    Learning objectives:

    1. Discuss the basic concepts of next-generation sequencing
    2. Define the complexities of detecting somatic mutations using tumor-derived DNA
    3. Describe the advantages and limitations of clinical NGS for precision oncology
     


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    Loading Comments...
    Show Resources